6533b829fe1ef96bd1289afd

RESEARCH PRODUCT

PSA and second-line therapy of hormone refractory prostate carcinoma

G. PomaraDarvinio MelloniVincenzo SerrettaG. ContinoMichele Pavone-macalusoI. RizzoCarlo Pavone

subject

OncologyMalemedicine.medical_specialtyPathologyHormone refractorymedicine.drug_classUrologyAdenocarcinomaAntiandrogenSettore MED/24 - UrologiaPSAProstateInternal medicineCarcinomamedicineHumansHormone refractoryBone painAgedAged 80 and overPerformance statusbusiness.industryProstateProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseProstate-specific antigenmedicine.anatomical_structureProstatic adenocarcinomaAdenocarcinomamedicine.symptombusiness

description

The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was 4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient. Copyright © 2001 S. Karger AG, Basel.

yearjournalcountryeditionlanguage
2001-04-24
10.1159/000056591http://hdl.handle.net/10447/201359